New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
09:21 EDTEXASFDA says Exact Sciences colorectal cancer screening tool study met objectives
Exact Sciences' Deep-C study met the primary objectives with respect to both required sensitivity and specificity of the company's Cologuard test compared to colonoscopy, FDA staff wrote in briefing documents ahead of the March 27 meeting of the Molecular and Clinical Advisory Committee Panel. With respect to the secondary objectives, Cologuard sensitivity is higher than FIT for both CRC and AA, FDA staff noted. Cologuard is an in vitro diagnostic device designed to analyze patientsí stool for the presence of colorectal cancer. Reference Link
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
08:05 EDTEXASMDVIP announces Cologuard to be availble by perscription
Subscribe for More Information
October 21, 2014
10:53 EDTEXASExact Sciences, Lumber Liquidators shorts recomended by Tilson, Bloomberg says
Kase Capital's Whitney Tilson recommended short positions in Exact Sciences (EXAS) and Lumber Liquidators (LL) while speaking at the Robin Hood Conference, according to Bloomberg.
October 16, 2014
11:21 EDTEXASOptions with decreasing implied volatility: EXAS ATLS LOCO MAT
Subscribe for More Information
07:02 EDTEXASExact Sciences CEO Conroy to be interviewed
CEO Conroy discusses the development of Cologuard, the first and only FDA approved, noninvasive stool DNA screening test for colorectal cancer in an interview on The Traders Network to be held on October 16 at 7:30 am. Webcast Link
October 15, 2014
11:27 EDTEXASOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INO ATLS LOCO OPK INFY EUO FDO
October 14, 2014
11:17 EDTEXASOptions with decreasing implied volatility
Subscribe for More Information
October 13, 2014
12:01 EDTEXASOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INFY YUM FDO HSY
07:31 EDTEXASExact Sciences price target raised to $42 from $25 at Benchmark Co.
Benchmark Co. raised its price target for Exact Sciences shares to $42 citing the Medicare coverage decision and reimbursement rate of $502 for the company's test. The firm had previously modeled a price of $300 for Cologuard. It reiterates a Buy rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use